Knight Therapeutics Dividend
Dividend criteria checks 0/6
Knight Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
5.2%
Buyback Yield
| Total Shareholder Yield | 5.2% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend updates
No updates
Recent updates
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?
May 28
Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why
May 07Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)
Apr 07Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares
Mar 20If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%
Mar 02Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 03
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?
Jan 19What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?
Jan 04A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)
Dec 20The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares
Dec 07What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Dec 02Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021
Nov 17Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if GUD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GUD's dividend payments have been increasing.
Dividend Yield vs Market
| Knight Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (GUD) | n/a |
| Market Bottom 25% (CA) | 1.8% |
| Market Top 25% (CA) | 6.1% |
| Industry Average (Pharmaceuticals) | 2.3% |
| Analyst forecast (GUD) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate GUD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GUD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate GUD's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GUD has not reported any payouts.